EMT6/AR1.0 was derived from the mouse mammary tumour cell line EMT6/P (Sigma Catalogue number. 96042344) by growth in increasing amounts of doxorubicin over a period of 8 weeks. The cell line showed a 40-fold greater resistance to doxorubicin, which is also known as adriamycin. The line was reported to express a classical multi-drug resistance (MDR) phenotype with hyperexpression of membrane P-glycoprotein and a spectrum of cross-resistance e.g. against vincristine and colchicine. Overexpression of CP22 (sorcin) and mdr 1a gene was reported. Cells were shown to have a reduced intracellular drug accumulation and exhibit a doubling time of 12-15 hours. It is recommended to culture the cells without drug after resuscitation until the first passage.
Split sub-confluent cultures (70-80%) 1:3 to 1:6 using 0.25% trypsin or trypsin/EDTA; 5% CO2; 37ºC. Resuscitate in drug-free medium, add doxorubicin after first passage.
Other Notes
Additional freight & handling charges may be applicable for Asia-Pacific shipments. Please check with your local Customer Service representative for more information.
Choose from one of the most recent versions:
Certificates of Analysis (COA)
Lot/Batch Number
It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.